Selected article for: "human immunodeficiency and immune system"
Author: D'Souza, M. Patricia; Palin, Amy C.; Calder, Thomas; Golding, Hana; Kleinstein, Steven H.; Milliken, Erin L.; O'Connor, David; Tomaras, Georgia; Warren, Jon; Boggiano, Cesar
Title: Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases
  • Cord-id: dt0o0ubm
  • Document date: 2021_8_6
    • ID: dt0o0ubm
    Snippet: Modern vaccinology has experienced major conceptual and technological advances over the past 30 years. These include atomic-level structures driving immunogen design, new vaccine delivery methods, powerful adjuvants, and novel animal models. In addition, utilizing advanced assays to learn how the immune system senses a pathogen and orchestrates protective immunity has been critical in the design of effective vaccines and therapeutics. The National Institute of Allergy and Infectious Diseases of
    Document: Modern vaccinology has experienced major conceptual and technological advances over the past 30 years. These include atomic-level structures driving immunogen design, new vaccine delivery methods, powerful adjuvants, and novel animal models. In addition, utilizing advanced assays to learn how the immune system senses a pathogen and orchestrates protective immunity has been critical in the design of effective vaccines and therapeutics. The National Institute of Allergy and Infectious Diseases of the National Institutes of Health convened a workshop in September 2020 focused on next generation assays for vaccine development (Table 1). The workshop focused on four critical pathogens: severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and human immunodeficiency virus (HIV)—which have no licensed vaccines—and tuberculosis (TB) and influenza—both of which are in critical need of improved vaccines. The goal was to share progress and lessons learned, and to identify any commonalities that can be leveraged to design vaccines and therapeutics.

    Search related documents:
    Co phrase search for related documents
    • activ public private partnership and acute respiratory syndrome coronavirus: 1
    • activ public private partnership vaccines and acute respiratory syndrome coronavirus: 1
    • activation immune activation and acute respiratory syndrome coronavirus: 1
    • activation induce and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • activation induce and adaptive immune response: 1, 2, 3, 4
    • acute respiratory syndrome coronavirus and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and adaptive immune response interrogate: 1, 2
    • acute respiratory syndrome coronavirus and additional understanding: 1, 2
    • acute respiratory syndrome coronavirus and adjuvant design: 1, 2, 3, 4
    • adaptive immune response and adjuvant design: 1